Showing 5231-5240 of 6808 results for "".
- Update: Two More Payers to Cover DermTech’s Melanoma Testhttps://practicaldermatology.com/news/update-two-more-payers-to-cover-dermtechs-melanoma-test/2461514/Two new payers plan to cover the DermTech Melanoma Test, making the foundational assay available to approximately 1.2 million more people. The new insurers are Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. T
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). T
- La Roche Posay Celebrates Second Annual National HA Day on Jan. 21, 2023https://practicaldermatology.com/news/la-roche-posay-celebrates-second-annual-national-ha-day-on-jan-21-2023/2461510/La Roche-Posay is ringing in its second annual National Hyaluronic Acid Day on January 21st. To celebrate National Hyaluronic Acid Day, the brand is offering 20% off on orders of $65 or more on
- Simple Laser Treatments May Help Prevent Nonmelanoma Skin Cancerhttps://practicaldermatology.com/news/simple-laser-treatments-may-help-prevent-nonmelanoma-skin-cancer/2461508/Nonablative fractional lasers treatments may help prevent basal cell carcinoma and squamous cell carcinoma, a new study suggests. Nonablative fractional lasers (NAFL) are currently used to treat scars, sun-damaged skin, age spots, and more; however, their effectiveness for pre
- Investigational Topical Peptide May Help Tame Eczemahttps://practicaldermatology.com/news/investigational-topical-peptide-may-help-tame-eczema/2461503/A new investigational topical peptide may can block inflammatory signaling in a preclinical model of atopic dermatitis – eczema, researchers at Vanderbilt University Medical Center (VUMC) report. Treatment for severe cases of eczema includes immunosuppressive drugs
- Algae May Enhance Skin Regeneration and Wound Healing: Studyhttps://practicaldermatology.com/news/algae-may-enhance-skin-regeneration-and-wound-healing-study/2461496/Euglena gracilis may enhance skin regeneration to speed wound healing, according to new research. Investigators developed a system based on microvesicles that bud from the cell surface of Euglena gracilis, a freshwater single-celled green algae, and conta
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no
- Sofwave Scores FDA Clearance to Improve Cellulitehttps://practicaldermatology.com/news/sofwave-scores-fda-clearance-to-improve-cellulite/2461488/Sofwave’s SUPERB technology is now US Food and Drug Administration (FDA)-cleared to improve the appearance of cellulite. SUPERB (Synchronous Ultrasound Parallel Beam) technology couples cooled transducers directly to the epidermis, creating a unique 3D arr
- Regenerative Medicine in Action: Scars Faded Using Transplanted Hair Follicleshttps://practicaldermatology.com/news/regenerative-medicine-in-action-scars-faded-using-transplanted-hair-follicles/2461486/Skin scars began to behave more like uninjured skin after they were treated with hair follicle transplants in a small new study. The scarred skin harboured new cells and blood vessels, remodelled collagen to restore healthy patterns, and even expressed genes found in healthy unscarred s
- Acelyrin Inc. to Accelerate Development of Izokibep in HShttps://practicaldermatology.com/news/acelyrin-incs-to-accelerate-development-of-izokibep-in-hs/2461484/Acelyrin Inc’s Izokibep achieved higher orders of Hidradenitis Suppurativa Clinical Responses (HiSCR) in open label Part A of a Phase 2b/3 trial. Izokibep has been administered to over 300 patients, some for up to three years. It is a small therapeutic protein inhibitor